January 9th, 2015
FDA Approves New Oral Anticoagulant from Daiichi Sankyo
Larry Husten, PHD
And then there were four. Late Thursday the FDA announced that it had approved edoxaban, the new oral anticoagulant manufactured by Daiichi Sankyo. The drug will be marketed under the brand name of Savaysa and joins three other new drugs in the large and important new oral anticoagulant marketplace: dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). All four drugs were […]
November 6th, 2014
Agent Could Potentially Reverse Anticoagulation Associated with Edoxaban
PER977 — a cation that binds to all of the new oral anticoagulants and heparin — may help reverse the anticoagulant effects of edoxaban, according to results of an industry-conducted trial published in the New England Journal of Medicine. Edoxaban, an oral factor Xa inhibitor, was recently recommended for approval by an FDA advisory panel. Researchers […]
October 31st, 2014
FDA Advisory Panel Gives Tepid Support to New Anticoagulant
Larry Husten, PHD
On Thursday the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 9-1 in favor of approval for Daiichi Sankyo’s edoxaban (Savaysa). The outcome will likely result in a drug that will be on the market, but that few physicians will prescribe until further studies are performed. Edoxaban will almost certainly become the fourth new oral anticoagulant (NOAC) to […]
December 5th, 2013
Large Study Finds Favorable Risk-Benefit Profile for the New Anticoagulants
Larry Husten, PHD
A very large new meta-analysis finds a favorable risk-benefit for the new oral anticoagulant drugs in the setting of atrial fibrillation. The findings, published online in the Lancet, were remarkably consistent for all four of the new agents which have been fighting to replace warfarin, which was the only oral anticoagulant available for decades until the arrival of […]
November 26th, 2013
Edoxaban and the Changing Landscape of Novel Anticoagulants for Atrial Fibrillation
Christian Thomas Ruff, MD, MPH
Christian Thomas Ruff, a coauthor of the ENGAGE AF-TIMI 48 trial of edoxaban versus warfarin in patients with atrial fibrillation, discusses the future of novel anticoagulants.
November 19th, 2013
Another New Anticoagulant Works Well in AF Patients
Larry Husten, PHD
Edoxaban, a direct oral factor Xa inhibitor, is the latest in the series of new oral anticoagulants seeking to take over the troubled role of warfarin in clinical practice. The results of ENGAGE-AF-TIMI 48 were presented at the American Heart Association meeting in Dallas and published simultaneously in the New England Journal of Medicine. In the trial, more than 21,000 […]
October 14th, 2013
Selections from Richard Lehman’s Literature Review: October 14th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include CRT in HF with a narrow QRS complex, a trial of edoxaban vs. warfarin for symptomatic VTE, and more.
September 18th, 2013
Is Edoxaban the Most Promising of the Novel Anticoagulants?
Samuel Goldhaber, MD
Samuel Z. Goldhaber offers his perspective on the Hokusai-VTE randomized trial comparing edoxaban and warfarin in patients with symptomatic venous thromboembolism.
September 1st, 2013
Positive Results for Edoxaban in VTE/PE
Larry Husten, PHD
Findings from the Hokusai-VTE trial of edoxaban
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?